Spruce Biosciences, Inc. (SPRB)

Market Cap	3.12M
Revenue (ttm)	4.91M
Net Income (ttm)	-53.04M
Shares Out	42.23M
EPS (ttm)	-1.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,265,224
Average Volume	3,807,308
Open	0.0791
Previous Close	0.0791
Day's Range	0.0719 - 0.0797
52-Week Range	0.0570 - 0.8700
Beta	2.50
RSI	20.40
Earnings Date	May 9, 2025

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric clas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 21
• Stock Exchange: OTCMKTS
• Ticker Symbol: SPRB

Financial Performance

In 2024, Spruce Biosciences's revenue was $4.91 million, a decrease of -51.32% compared to the previous year's $10.09 million. Losses were -$53.04 million, 10.7% more than in 2023.